Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DNL151 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DNL151 Low Dose | EXPERIMENTAL | - |
| DNL151 Mid Dose | EXPERIMENTAL | - |
| DNL151 High Dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DNL151 | DRUG | Oral repeating dose |
| Placebo | DRUG | Oral repeating dose |
Key Inclusion Criteria: * Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive * Clinical diagnosis of Parkinson's disease meeting UK Brain Bank criteria and H\&Y Stage I, II, or III. * Able to hold Parkinson's disease medications 8 hours (overnight) prior to specific study assessments Key E...
DNL151 is an investigational small molecule being studied for the treatment of Parkinson's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. A completed Phase 1 trial evaluated its safety and tolerability in patients with Parkinson's Disease.
DNL151 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical research to evaluate the drug's potential as a treatment for Parkinson's Disease.
DNL151 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received regulatory approval and is still undergoing clinical evaluation for Parkinson's Disease.
DNL151 has one completed clinical trial registered as NCT04056689, titled 'Study to Evaluate DNL151 in Subjects With Parkinson's Disease.' This Phase 1 study enrolled 36 participants and was conducted in the United States, Belgium, Netherlands, and United Kingdom.
DNL151 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Parkinson's Disease. The drug has completed a Phase 1 trial but has not yet received marketing authorization from regulatory agencies.